CC-92328 for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called CC-92328 for individuals with multiple myeloma, a type of blood cancer, who have not responded to previous treatments. The study aims to determine the treatment's safety and effectiveness when used alone. Participants will receive the medication through an IV in 28-day cycles. Suitable candidates have multiple myeloma that has returned or not responded to other treatments, with their condition worsening within the last year. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that participants should not have had prior cancer treatments or investigational treatments within a certain time before starting the trial, which might imply a need to stop some medications. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that CC-92328 is likely to be safe for humans?
Research shows limited information on the safety of CC-92328, as it is currently being tested in humans for the first time. This Phase 1 study primarily assesses how well participants tolerate the treatment and identifies potential side effects. At this early stage, the main goal is to determine the treatment's safety at various doses.
Participants may experience some side effects, which is typical when testing a new treatment. Detailed safety information from past studies is unavailable because this is the first human trial of this treatment.
Prospective participants should discuss any concerns with the study team. The team can provide updates and support based on the latest findings as the trial progresses.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for multiple myeloma, which typically include drugs like lenalidomide, bortezomib, and dexamethasone, CC-92328 is unique because it introduces a novel mechanism of action. It is designed to be administered intravenously in 28-day cycles, providing a potentially new way to manage the disease. Researchers are excited about CC-92328 because it targets specific pathways involved in the growth and survival of myeloma cells, which could offer a promising new avenue for patients who have exhausted other treatments. This targeted approach might lead to better outcomes and fewer side effects compared to existing options.
What evidence suggests that CC-92328 might be an effective treatment for multiple myeloma?
Research shows that CC-92328 is a new treatment tested in this trial for relapsed and/or refractory multiple myeloma, a type of blood cancer. This drug aids the body's immune cells in attacking cancer cells, a promising method in cancer treatment. Limited information exists on CC-92328 itself, as it remains new in testing. However, similar treatments in early trials have shown promise, with some patients experiencing tumor shrinkage or disappearance. These early results suggest CC-92328 could potentially be effective for this condition, but further research is needed to confirm its effects.56789
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with relapsed or refractory multiple myeloma who have tried other treatments without success. They must be able to perform daily activities with ease (ECOG PS of 0 or 1), understand the study, and follow its schedule. Women who can become pregnant and men must use effective birth control. People cannot join if they are pregnant, recently had certain vaccines or transplants, weigh under 40 kg, have active hepatitis B/C, HIV, or MM affecting the brain.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Monotherapy Dose Escalation (Part A)
Participants receive escalating doses of CC-92328 to determine the maximum tolerated dose
Monotherapy Dose Expansion (Part B)
Participants receive the determined dose of CC-92328 to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CC-92328
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania